“Upon FDA authorization, we believe it will contribute meaningfully to Helix' growth.”

In context

“in [ oral ] tobacco industry volume over the past 6 months. Helix grew [ on! ] reported shipment volume to approximately 33 million cans during the first quarter, an increase of 32%. on! continued its momentum at [ retail ], growing its share of the oral tobacco category by 0.7 share points to 7.1%. Helix delivered these impressive results as on! retail price increased by 26%. This spring, Helix introduced a new trade program that secures premium positioning for on! in over 80% of contracted stores, creating broader visibility of the brand. Helix is continuing its focus on strategically investing behind the brand as the category growth accelerates. Helix is also making final preparations for following its PMTA for on! PLUS, which we expect to submit in the first half of this year. Upon FDA authorization, we believe it will contribute meaningfully to Helix' growth. We continue to aggressively pursue efforts to create the conditions for tobacco harm reductions success in the U.S., to benefit tobacco consumers, society and our shareholders. I am confident in Altria's ability to lead the way in harm reduction with our exciting portfolio of smoke-free products and our talented and dedicated employees. With our smoke-free progress and the strength of our traditional tobacco businesses in mind, we reaffirm our guidance to deliver 2024, full year adjusted diluted EPS in the range of $5.05 to $5.17, representing a growth rate of 2% to 4.5% from a base of $4.95 in 2023. I'll now turn it over to Sal to provide more details on the business environment and our results. Salvatore Mancuso: Thank, Billy. First quarter adjusted diluted earnings per share de”